Living-donor kidney transplant from hepatitis B surface antigen-positive donors to hepatitis B antibody-positive recipients without hepatitis B immunoglobulin prophylaxis in an endemic country

Heungman Jun, Myung-Gyu Kim, Kwan Tae Park, Cheol Woong Jung

Research output: Contribution to journalArticle

Abstract

Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. Materials and Methods: In the years between 2012 and 2013, we transplanted 4 renal grafts from hepatitis B surface antigen-positive living donors to antihepatitis B antibody-positive recipients. Lamivudine was prescribed for recipients after transplant without hepatitis B immuno globulin. Results: In 1-year follow-up, there were no abnormal findings in the levels of renal and liver enzymes, and there was no unwanted seroconversion to positive hepatitis B surface antigen. Conclusions: When combined with careful hepatitis B virus-monitoring, renal grafts from hepatitis B surface antigen-positive living donors can be transplanted to hepatitis B antibody-positive recipients, without the need for hepatitis B immunoglobulin prophylaxis, in a hepatitis B virus endemic country.

Original languageEnglish
Pages (from-to)256-258
Number of pages3
JournalExperimental and Clinical Transplantation
Volume13
DOIs
Publication statusPublished - 2015 Jan 1

    Fingerprint

Keywords

  • End-stage renal disease
  • Infectious diseases
  • Lamivudine

ASJC Scopus subject areas

  • Transplantation

Cite this